CD274 and cancer: Some evidence suggested the potential association of PD-L1 positivity with reduced BCRFS/MFS/CSS [38,56,86,89,93], thus arguing that the disruption of anti-tumor immunity exerted by PD-L1 expressed on cancer cells is an underlying mechanism of tumor recurrence [178].